Abstract: The present disclosure relates to a novel murine parvovirus, sequences encoded thereby, and applications therefor. In one embodiment the disclosure provides a method for detecting the presence of a parvovirus in a sample, comprising detecting one or more nucleic acids or polypeptides derived from the parvovirus, or antibodies against the parvovirus, in the sample. Also provided are vectors and host cells comprising sequences encoded by the parvovirus and related sequences. Also provided are animal models of kidney disease associated with infection by the parvovirus.

Abstract: The invention relates to the identification of antigens, including Mycobacterium sulphate assimilation pathway components such as CysD, for preventing and treating Mycobacterium infection, especially but not exclusively Mycobacterium tuberculosis infection; to expression systems including live Mycobacterium for expression of said antigens for prevention and treatment of said infection; and to use of said antigens and expression systems for prevention and treatment of said infection.

Abstract: The invention relates to the identification of antigens, including Mycobacterium sulphate assimilation pathway components such as CysD, for preventing and treating Mycobacterium infection, especially but not exclusively Mycobacterium tuberculosis infection; to expression systems including live Mycobacterium for expression of said antigens for prevention and treatment of said infection; and to use of said antigens and expression systems for prevention and treatment of said infection.

Abstract: The present invention relates to methods for modulating angiogenesis, comprising administering to a subject, or cells or tissue derived therefrom: (i) one or more miRNA, or precursors or variants thereof, wherein at least one of said miRNA comprises a seed region comprising the sequence UCACAGU (SEQ ID NO:37) to inhibit angiogenesis; or (ii) one or more antagonists of a miRNA, wherein said miRNA comprises a seed region comprising the sequence UCACAGU (SEQ ID NO:37) to promote or induce angiogenesis. Also provided are methods of diagnosis of conditions associated with abnormal angiogenesis, or determining predisposition thereto. Suitable pharmaceutical compositions are also provided.

Abstract: The present invention relates to methods and kits for identifying, quantifying and isolating regulatory T cells, to methods and kits for diagnosing or monitoring autoimmune diseases, immunoinflammatory diseases, allergic diseases, predispositions thereto, infectious diseases, cancer, cancer treatment and/or organ transplantation based on regulatory T cell quantity, to methods and kits for predicting responses to therapy for autoimmune diseases, immunoinflammatory diseases, allergic diseases, predispositions thereto, infectious diseases, cancer and/or organ transplantation based on regulatory T cell quantity, and to methods and kits for therapy using isolated regulatory T cells.

Abstract: The present invention relates to methods for modulating angiogenesis, comprising administering to a subject, or cells or tissue derived therefrom: (i) one or more miRNA, or precursors or variants thereof, wherein at least one of said miRNA comprises a seed region comprising the sequence UCACAGU (SEQ ID NO:37) to inhibit angiogenesis; or (ii) one or more antagonists of a miRNA, wherein said miRNA comprises a seed region comprising the sequence UCACAGU (SEQ ID NO:37) to promote or induce angiogenesis. Also provided are methods of diagnosis of conditions associated with abnormal angiogenesis, or determining predisposition thereto. Suitable pharmaceutical compositions are also provided.

Abstract: The present invention relates to methods and kits for identifying, quantifying and isolating regulatory T cells, to methods and kits for diagnosing or monitoring autoimmune diseases, immunoinflammatory diseases, allergic diseases, predispositions thereto, infectious diseases, cancer, cancer treatment and/or organ transplantation based on regulatory T cell quantity, to methods and kits for predicting responses to therapy for autoimmune diseases, immunoinflammatory diseases, allergic diseases, predispositions thereto, infectious diseases, cancer and/or organ transplantation based on regulatory T cell quantity, and to methods and kits for therapy using isolated regulatory T cells.

Abstract: The present invention relates to methods and kits for identifying, quantifying and isolating regulatory T cells, to methods and kits for diagnosing or monitoring autoimmune diseases, immunoinflammatory diseases, allergic diseases, predispositions thereto, infectious diseases, cancer, cancer treatment and/or organ transplantation based on regulatory T cell quantity, to methods and kits for predicting responses to therapy for autoimmune diseases, immunoinflammatory diseases, allergic diseases, predispositions thereto, infectious diseases, cancer and/or organ transplantation based on regulatory T cell quantity, and to methods and kits for therapy using isolated regulatory T cells.

Abstract: The invention relates to a method for predicting a response to a proteasome inhibitor in the prophylaxis or treatment of a cancer in an individual. The method comprises providing a sample of cancer cells of the cancer from the individual, and evaluating the level of at least one molecule in the cancer cells associated with the unfolded protein response of the cancer cells, to provide test data indicative of the level of activity of the unfolded protein response. The test data is used to predict the response of the cancer cells to the proteasome inhibitor. The evaluation of the level of the molecule can be utilized for determination of treatment for the cancer.

Abstract: The present disclosure relates to compounds and methods for inhibiting the formation of miRNAs that inhibit translation of one or more identified proteins. The compounds comprise antisense oligonucleotides targeting the pri-miRNA precursor of miRNAs.

Abstract: The present invention relates generally to a method of immunomodulating therapy and pharmaceutical compositions useful for same. More particularly, the present invention provides a method of ameliorating the effects of autoimmune conditions. Even more particularly, the present invention contemplates a method for preventing, delaying onset of or otherwise ameliorating the effects of insulin-dependant diabetes mellitus (IDDM) by administering a cell wall subunit or a chemical or functional equivalent thereof from Mycobacterium or a related organism or other suitable biological source.

Abstract: The present invention relates generally to a method of immunomodulating therapy and pharmaceutical compositions useful for same. More particularly, the present invention provides a method of ameliorating the effects of autoimmune conditions. Even more particularly, the present invention contemplates a method for preventing, delaying onset of or otherwise ameliorating the effects of insulin-dependant diabetes mellitus (IDDM) by administering a cell wall subunit or a chemical or functional equivalent thereof from Mycobacterium or a related organism or other suitable biological source.

Abstract: Provided are methods for the preparation of immunoglobulins, including fully-human immunoglobulins, and immunoglobulins and compositions comprising immunoglobulins prepared by these methods. Also provided are libraries of immunoglobulins and immunoglobulin expressing cells as well as methods and vector constructs for preparation of these libraries. Immunoglobulins provided herein are useful inter alia as immunological and diagnostic agents and as therapeutic molecules in the treatment of diseases such as autoimmune diseases, heart disease, infections and cancers.

Abstract: Provided are single-chain Fv (scFv) fragment-based compositions and methods for targeting antigens to antigen-presenting cells (APCs) such as, for example, dendritic cells (DC). Compositions and methods disclosed herein are useful in the treatment of diseases including infectious diseases and cancer.